Increase in ampC promoter strength due to mutations and deletion of the attenuator in a clinical isolate of cefoxitin-resistant Escherichia coli as determined by RT–PCR
Open Access
- 1 May 2005
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 55 (5) , 768-772
- https://doi.org/10.1093/jac/dki074
Abstract
Objectives: To characterize the mechanism of cefoxitin resistance in clinical isolate Escherichia coli N99-0001. Methods: Plasmid analysis, PCR for β-lactamases, and sequencing of the ampC genes was carried out. An RT–PCR method was developed to determine relative ampC expression. Results: Analysis of the ampC promoter region of E. coli N99-0001 revealed a T→A mutation at −32, a C→A mutation at −11, an insertion of a T between −20 and −21, and a 28 bp deletion including the entire attenuator. RT–PCR showed that ampC was expressed 140-fold higher in E. coli N99-0001 than in E. coli ATCC 25922. Conclusions: Cefoxitin resistance in E. coli N99-0001 was due to overexpression of ampC caused by an increase in promoter strength.Keywords
This publication has 9 references indexed in Scilit:
- Molecular Characterization of Cefoxitin-Resistant Escherichia coli from Canadian HospitalsAntimicrobial Agents and Chemotherapy, 2005
- Comparison of two RT-PCR methods for quantifyingampCspecific transcripts inEscherichia colistrainsFEMS Microbiology Letters, 2003
- High-Level Expression of AmpC β-Lactamase Due to Insertion of Nucleotides between −10 and −35 Promoter Sequences in Escherichia coli Clinical Isolates: Cases Not Responsive to Extended-Spectrum-Cephalosporin TreatmentAntimicrobial Agents and Chemotherapy, 2003
- −11 Mutation in theampCPromoter Increasing Resistance to β-Lactams in a ClinicalEscherichia coliStrainAntimicrobial Agents and Chemotherapy, 2002
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001
- Molecular mechanisms of cefoxitin resistance in Escherichia coli from the Toronto area hospitalsDiagnostic Microbiology and Infectious Disease, 2001
- Analysis of the effects of -42 and -32 ampC promoter mutations in clinical isolates of Escherichia coli hyperproducing AmpCJournal of Antimicrobial Chemotherapy, 2000
- Mutations in the ampC promoter of Escherichia coli isolates resistant to oxyiminocephalosporins without extended spectrum β-lactamase productionFEMS Microbiology Letters, 1999
- Molecular Basis of AmpC Hyperproduction in Clinical Isolates of Escherichia coliAntimicrobial Agents and Chemotherapy, 1999